Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis
Kidney Protection Benefits GLP-1 drugs can help protect your kidneys in several ways: They promote sodium excretion (diuresis) They reduce protein in the urine (a sign of kidney damage) They help lower blood pressure, which reduces strain on kidneys They have anti-inflammatory effects that can protect kidney cells Research has found that liraglutide reduced the risk of kidney disease progression by 26% in people with type 2 diabetes and heart disease
18 October 2023
This is still a Peptide that needs to be researched, and as the Peptide sciences increase, this might be more common in the ED treatment world
